(RVNC)—Based on all of the information at my disposal, I expect DWP-415 to be, at most, a minor player in the US botulinum-toxin market with a market share comparable to Xeomin. The business model you describe is consistent with such a view, IMO.
(RVNC)—Daewoo recently received an FDA Form-483 citation for an issue at the Korean plant where Evolus’ botulinum toxin, DWP-415 is made, according to Wells Fargo.
Market Data 
Markets 
AI
